Publications | PubMed=222778; DOI=10.1002/jcp.1040990107 Stein G.H. T98G: an anchorage-independent human tumor cell line that exhibits stationary phase G1 arrest in vitro. J. Cell. Physiol. 99:43-54(1979) PubMed=3413074; DOI=10.1073/pnas.85.16.6042 Pereira-Smith O.M., Smith J.R. Genetic analysis of indefinite division in human cells: identification of four complementation groups. Proc. Natl. Acad. Sci. U.S.A. 85:6042-6046(1988) PubMed=9090379; DOI=10.1038/ng0497-356 Steck P.A., Pershouse M.A., Jasser S.A., Yung W.-K.A., Lin H., Ligon A.H., Langford L.A., Baumgard M.L., Hattier T., Davis T., Frye C., Hu R., Swedlund B., Teng D.H.-F., Tavtigian S.V. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 15:356-362(1997) PubMed=9842975; DOI=10.1002/(SICI)1097-0215(19981218)79:6<640::AID-IJC15>3.0.co;2-z Weller M., Rieger J., Grimmel C., Van Meir E.G., De Tribolet N., Krajewski S., Reed J.C., von Deimling A., Dichgans J. Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses. Int. J. Cancer 79:640-644(1998) DOI=10.1007/0-306-46861-1_11 Ali-Osman F. Brain tumors. (In) Human cell culture. Vol. 2. Cancer Cell Lines part 2; Masters J.R.W., Palsson B.O. (eds.); pp.167-184; Kluwer Academic Publishers; New York (1999) PubMed=10416987; DOI=10.1111/j.1750-3639.1999.tb00536.x Ishii N., Maier D., Merlo A., Tada M., Sawamura Y., Diserens A.-C., Van Meir E.G. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol. 9:469-479(1999) PubMed=10560660; DOI=10.1097/00005072-199911000-00007 Schmidt E.E., Ichimura K., Goike H.M., Moshref A., Liu L., Collins V.P. Mutational profile of the PTEN gene in primary human astrocytic tumors and cultivated xenografts. J. Neuropathol. Exp. Neurol. 58:1170-1183(1999) PubMed=11414198; DOI=10.1007/s004320000207 Lahm H., Andre S., Hoeflich A., Fischer J.R., Sordat B., Kaltner H., Wolf E., Gabius H.J. Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures. J. Cancer Res. Clin. Oncol. 127:375-386(2001) PubMed=14614447; DOI=10.1038/sj.onc.1207198 Wischhusen J., Naumann U., Ohgaki H., Rastinejad F., Weller M. CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death. Oncogene 22:8233-8245(2003) PubMed=14655754; DOI=10.1111/j.1750-3639.2003.tb00479.x Bahr O., Rieger J., Duffner F., Meyermann R., Weller M., Wick W. P-glycoprotein and multidrug resistance-associated protein mediate specific patterns of multidrug resistance in malignant glioma cell lines, but not in primary glioma cells. Brain Pathol. 13:482-494(2003) PubMed=14961077; DOI=10.1038/sj.onc.1207244 Wang Y.-L., Zhu S.-J., Cloughesy T.F., Liau L.M., Mischel P.S. p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition. Oncogene 23:1283-1290(2004) PubMed=16232199; DOI=10.1111/j.1349-7006.2005.00099.x Saigusa K., Hashimoto N., Tsuda H., Yokoi S., Maruno M., Yoshimine T., Aoyagi M., Ohno K., Imoto I., Inazawa J. Overexpressed Skp2 within 5p amplification detected by array-based comparative genomic hybridization is associated with poor prognosis of glioblastomas. Cancer Sci. 96:676-683(2005) PubMed=17595512; DOI=10.1159/000104150 Rieger J., Frank B., Weller M., Wick W. Mechanisms of resistance of human glioma cells to Apo2 ligand/TNF-related apoptosis-inducing ligand. Cell. Physiol. Biochem. 20:23-34(2007) PubMed=18445040; DOI=10.1111/j.1742-4658.2008.06452.x Kikuchi Y., Kakeya T., Nakajima O., Sakai A., Ikeda K., Yamaguchi N., Yamazaki T., Tanamoto K., Matsuda H., Sawada J., Takatori K. Hypoxia induces expression of a GPI-anchorless splice variant of the prion protein. FEBS J. 275:2965-2976(2008) PubMed=19435942; DOI=10.1215/15228517-2009-025 Ichimura K., Pearson D.M., Kocialkowski S., Backlund L.M., Chan R., Jones D.T.W., Collins V.P. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro-oncol. 11:341-347(2009) PubMed=20164919; DOI=10.1038/nature08768 Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R. Signatures of mutation and selection in the cancer genome. Nature 463:893-898(2010) PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458 Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A. A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers. Cancer Res. 70:2158-2164(2010) PubMed=20587068; DOI=10.1186/1471-2407-10-339 Nakabayashi H., Yawata T., Shimizu K. Anti-invasive and antiangiogenic effects of MMI-166 on malignant glioma cells. BMC Cancer 10:339.1-339.9(2010) PubMed=22460905; DOI=10.1038/nature11003 Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483:603-607(2012) PubMed=22570425; DOI=10.1093/neuonc/nos072 Bady P., Diserens A.-C., Castella V., Kalt S., Heinimann K., Hamou M.-F., Delorenzi M., Hegi M.E. DNA fingerprinting of glioma cell lines and considerations on similarity measurements. Neuro-oncol. 14:701-711(2012) PubMed=25984343; DOI=10.1038/sdata.2014.35 Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C. Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Sci. Data 1:140035-140035(2014) PubMed=25485619; DOI=10.1038/nbt.3080 Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M. A comprehensive transcriptional portrait of human cancer cell lines. Nat. Biotechnol. 33:306-312(2015) PubMed=25894527; DOI=10.1371/journal.pone.0121314 Bausch-Fluck D., Hofmann A., Bock T., Frei A.P., Cerciello F., Jacobs A., Moest H., Omasits U., Gundry R.L., Yoon C., Schiess R., Schmidt A., Mirkowska P., Hartlova A., Van Eyk J.E., Bourquin J.-P., Aebersold R., Boheler K.R., Zandstra P.W., Wollscheid B. A mass spectrometric-derived cell surface protein atlas. PLoS ONE 10:E0121314-E0121314(2015) PubMed=26496030; DOI=10.18632/oncotarget.6171 Patil V., Pal J., Somasundaram K. Elucidating the cancer-specific genetic alteration spectrum of glioblastoma derived cell lines from whole exome and RNA sequencing. Oncotarget 6:43452-43471(2015) PubMed=26589293; DOI=10.1186/s13073-015-0240-5 Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C. TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression. Genome Med. 7:118.1-118.7(2015) PubMed=27397505; DOI=10.1016/j.cell.2016.06.017 Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J. A landscape of pharmacogenomic interactions in cancer. Cell 166:740-754(2016) PubMed=27412690; DOI=10.1074/mcp.M116.060350 Shraibman B., Kadosh D.M., Barnea E., Admon A. Human leukocyte antigen (HLA) peptides derived from tumor antigens induced by inhibition of DNA methylation for development of drug-facilitated immunotherapy. Mol. Cell. Proteomics 15:3058-3070(2016) PubMed=28464039; DOI=10.1371/journal.pone.0176683 Hill V.K., Kim J.-S., James C.D., Waldman T. Correction of PTEN mutations in glioblastoma cell lines via AAV-mediated gene editing. PLoS ONE 12:E0176683-E0176683(2017) PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747 Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A. An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines. Cancer Res. 79:1263-1273(2019) PubMed=31068700; DOI=10.1038/s41586-019-1186-3 Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 569:503-508(2019) PubMed=33385022; DOI=10.1016/j.dib.2020.106643 de Sousa J.F., da Silva P., Serafim R.B., Nociti R.P., Moreira C.G., Silva W.A., Valente V. RNA sequencing data of different grade astrocytoma cell lines. Data Brief 34:106643.1-106643.13(2021) PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010 Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R. Pan-cancer proteomic map of 949 human cell lines. Cancer Cell 40:835-849.e8(2022) |